title: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study.
abstract: A 16-week, double-blind, placebo controlled, dose titration study was done on 100 normotensive patients age 45 years or older to determine the efficacy and safety of doxazosin, a selective alpha 1-adrenoceptor antagonist, in the treatment of benign prostatic hyperplasia (BPH). Of the 41 efficacy evaluable patients 88% underwent dose titration to a maximum of 8 mg. doxazosin once daily. Maximum and average urinary flow rates increased significantly above baseline with doxazosin (2.9 ml. per second and 1.4 ml. per second, respectively) compared with placebo (0.7 ml. per second and 0.3 ml. per second, respectively). A significant effect on maximum flow rate was noted as early as week 2 of double-blind treatment at the initial efficacy evaluation. Doxazosin was superior to placebo in patient and investigator assessments of total, obstructive and irritative BPH symptoms. The onset of efficacy for total patient-assessed symptoms was significant for doxazosin compared to placebo 4 weeks after the start of the treatment regimen. Statistically significant decreases in mean blood pressure of 4 to 6 mm. Hg were noted with doxazosin compared with placebo. Adverse events, primarily mild to moderate in severity, were reported in 44% of patients given doxazosin and 30% of those given placebo. Our results strongly demonstrate that doxazosin is significantly superior to placebo in the treatment of BPH in normotensive patients, with the patient experiencing significant relief early after initiation of therapy.
authors.affiliation: Department of Urology, Louisiana State University Medical Center, New Orleans, USA.
authors.forename: A
authors.initials: A
authors.lastname: Fawzy
authors.forename: K
authors.initials: K
authors.lastname: Braun
authors.forename: G P
authors.initials: GP
authors.lastname: Lewis
authors.forename: M
authors.initials: M
authors.lastname: Gaffney
authors.forename: K
authors.initials: K
authors.lastname: Ice
authors.forename: N
authors.initials: N
authors.lastname: Dias
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D017292:Doxazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010919:Placebos; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012449:Safety; D014554:Urination / Q000187:drug effects; D014555:Urination Disorders / Q000188:drug therapy
chemical_list: D010919:Placebos; D017292:Doxazosin